NCT03879811View on ClinicalTrials.gov

Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 13, 2019

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Colorectal Cancer
Interventions
DRUG

TMZ

Oral TMZ at 150mg/m2

DRUG

Nivolumab

Nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER